Navigation Links
The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
Date:6/16/2008

Kleiner-Perkins, Highland Capital Fund Company Focused on iPS Technology

SAN FRANCISCO, June 16 /PRNewswire/ -- iZumi Bio, Inc., and The J. David Gladstone Institutes, an independent non-profit biomedical research organization, have announced a major research collaboration and licensing agreement to focus on applications for induced pluripotent stem (iPS) cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080616/AQM126LOGO)

iPS cells are "reprogrammed" adult cells that have similar properties and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to avoid immune rejection.

"The Gladstone relationship with iZumi Bio combines our work in cardiovascular disease and stem cell science with first-class investors and an experienced management team," said Deepak Srivastava, MD, Director of the Gladstone Institute of Cardiovascular Disease (GICD). "It's an ideal model for advancing science in a focused, efficient way."

"Gladstone is emerging as a global leader in regenerative medicine and its applications to heart disease," said Thane Kreiner, PhD, iZumi Bio Chief Executive Officer. "This collaboration underscores our commitment and ability to translate the best research in iPS technology to products that address important unmet medical needs."

Elements of the broad partnership include iZumi Bio taking a license to certain Gladstone patents and sponsoring research related to iPS cells and cardiovascular disease. Dr. Srivastava will lead the research and will join iZumi Bio's scientific advisory board.

"We're delighted to add this important new company to our translational research partners," said Gladstone President, Robert W. Mahley, MD, PhD. "We look forward to developing iPS technology into treatments and cures."

About the Gladstone Institutes

The J. David Gladstone Institutes, affiliated with the University of California, San Francisco (UCSF), is dedicated to the health and welfare of humankind through research into the causes and prevention of some of the world's most devastating diseases. Gladstone is composed of the Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology, and the Gladstone Institute of Neurological Disease. Two years ago, Gladstone formed the Center for Translational Research to create collaborations with biotechnology and pharmaceutical partners for preclinical development for its most promising therapeutic research candidates. More information can be found at http://www.gladstone.ucsf.edu.

About iZumi

iZumi Bio, Inc. was founded in 2007 and is funded by Kleiner Perkins Caufield and Byers and Highland Capital Partners. iZumi is using the power of induced pluripotent stem cells (iPS) to transform drug discovery and regenerative medicine. The name iZumi, which means "fountain of youth", was chosen to honor the Japanese origins of iPS technology. iZumi is located in the San Francisco Bay Area. More information will become available at http://www.izumibio.com.


'/>"/>
SOURCE iZumi Bio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gladstone scientists identify role of tiny RNAs in controlling stem cell fate
2. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
3. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
4. UNC-Chapel Hill, Hamner Institutes Announce Partnership to Accelerate Basic, Translational Research
5. National Institutes of Health Awards $25.5M Contract to SRA
6. EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
7. Haemonetics Announces Launch of Faster Plasma Collection Protocol
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
10. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
11. Villa St. Benedict Announces New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):